Based on our data and given the fact that SIRT1 could play a role in drug resistance related to its ability to deacetylate tumor suppressors, such as p53 [10], the current study aimed to find out whether sorafenib influences the NAMPT/SIRT1/AMPK signaling pathway and energy metabolism. Here, NAMPT is linked to neoplasm.